Dr. Kauffman and Dr. Shacham to depart Karyopharm on May 31, 2022

Karyopharm Therapeutics Inc.

Dr. Michael Kauffman to depart as Senior Clinical Advisor; receives 18 months salary at $646,875/yr.
Dr. Sharon Shacham to depart as CSO; receives 18 months salary at $519,901/yr and consulting role.
Both executives get accelerated vesting of equity awards; options exercisable until March 1, 2025.
Dr. Shacham receives new grants: 90,000 stock options and 60,000 RSUs under consulting agreement.
Dr. Kauffman resigned from Board on March 22, 2022; waived nomination rights.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Michael G. Kauffman

Senior Clinical Advisor

KPTI · Karyopharm Therapeutics Inc.

Effective: 2022-05-31
Filed: March 29, 2022, 7:59 PM ET

provides for Dr. Kauffman’s separation from employment as Senior Clinical Advisor on May 31, 2022

Departed

Sharon Shacham

Chief Scientific Officer

KPTI · Karyopharm Therapeutics Inc.

Effective: 2022-05-31
Filed: March 29, 2022, 7:59 PM ET

provides for Dr. Shacham’s separation from employment as Chief Scientific Officer on the Separation Date

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael G. Kauffman resigned as Senior Clinical Advisor at Karyopharm Therapeutics Inc..

Action: resigned
Role: Senior Clinical Advisor

Exact text from the filing

provides for Dr. Kauffman’s separation from employment as Senior Clinical Advisor on May 31, 2022

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Sharon Shacham resigned as Chief Scientific Officer at Karyopharm Therapeutics Inc..

Action: resigned
Role: Chief Scientific Officer

Exact text from the filing

provides for Dr. Shacham’s separation from employment as Chief Scientific Officer on the Separation Date

View on SEC.gov

Karyopharm Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-087458

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.